Drug Trial Radar · NCT06868199
A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
Last checked: Nov 19, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
87
Planned (sponsor's estimate)
Start
May 6, 2025
Primary completion
Aug 1, 2027
Study completion Feb 1, 2028
Sponsor
- Lead sponsor
- LaNova Medicines LimitedIndustry
- Sponsor type
- Industry
- First posted
- Mar 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
For phase I ,this study is to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D) and/or Maximum Tolerated Dose (MTD) for LM-168 as a single agent or in combination with toripalimab in subjects with advanced solid tumours. For phase II ,this study is to assess the preliminary anti-tumour activity of LM-168 as a single agent or in combination with toripalimab measured by objective response rate (ORR) in subjects with advanced solid tumours.
Conditions
- Advanced Solid Tumours
Interventions
LM-168Drug
Q3W,Intravenous Drip
ToripalimabDrug
Q3W,Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs)Time frame: 78 weeks
- Incidence of dose-limitingtoxicity (DLT)Time frame: 78 weeks
- Incidence of serious adverse event (SAE)Time frame: 78 weeks
- Temperature (Celsius)Time frame: 78 weeks
- Pulse in BPM(Beat per Minute)Time frame: 78 weeks
- Blood Pressure in mmHgTime frame: 78 weeks
- Weight in KgTime frame: 78 weeks
- Height in centimeterTime frame: 78 weeks
- Blood Routine examinationTime frame: 78 weeks
- Urine Routine testTime frame: 78 weeks
- Blood biochemistry testTime frame: 78 weeks
- Coangulation function testTime frame: 78 weeks
- Thyroid function testTime frame: 78 weeks
- Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentageTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in HRTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in RRTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in PRTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in QRSTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in QTTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in QTcFTime frame: 78 weeks
- ECOG(Eastern Cooperative Oncology Group) scoreTime frame: 78 weeks
- Objective Response Rate (ORR)Time frame: From 78th week to 130th week (52 weeks in total)
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Macquarie University
Ryde, New South Wales, Australia · Recruiting
MUPharm Pty Limited trading as Macquarie University Hospital Parmarcy
Ryde, New South Wales, Australia · Recruiting
Cancer Care Wollongong Pty Limited
Wollongong, New South Wales, Australia · Recruiting
Bayview Health-Investigational Drug Services
Perth, Western Australia, Australia · Recruiting
One Clinical Reasearch
Perth, Western Australia, Australia · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.